INSPECS GROUP PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 70.5 GBX | -2.08% |
|
-0.70% | -16.07% |
| Apr. 17 | AIM WINNERS & LOSERS: Inspecs confident but Scirocco eyes AIM exit | AN |
| Apr. 17 | Inspecs hails "encouraging" recent trading after tepid start to 2024 | AN |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- The stock, which is currently worth 2024 to 0.45 times its sales, is clearly overvalued in comparison with peers.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -16.07% | 91.2M | C- | ||
| +22.39% | 43.96B | B | ||
| -0.30% | 18.78B | B- | ||
| -20.50% | 2.22B | D+ | ||
| +25.60% | 2.11B | C+ | ||
| +19.17% | 1.13B | - | ||
| -38.32% | 716M | - | ||
| -10.65% | 645M | - | ||
| -44.53% | 632M | B- | ||
| +57.22% | 606M | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- SPEC Stock
- Ratings INSPECS Group plc
